Immunic’s (IMUX) Outperform Rating Reaffirmed at Wedbush

Immunic (NASDAQ:IMUXGet Rating)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research note issued on Friday, Zacks.com reports.

IMUX has been the subject of a number of other reports. Zacks Investment Research downgraded Immunic from a “hold” rating to a “sell” rating in a research note on Tuesday. StockNews.com initiated coverage on Immunic in a research note on Thursday, March 31st. They issued a “sell” rating for the company. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Immunic presently has a consensus rating of “Hold” and an average target price of $38.75.

NASDAQ IMUX opened at $5.98 on Friday. The business has a fifty day moving average price of $10.12 and a 200 day moving average price of $10.29. Immunic has a one year low of $5.88 and a one year high of $15.12. The company has a market cap of $182.63 million, a P/E ratio of -1.49 and a beta of 1.99.

Immunic (NASDAQ:IMUXGet Rating) last issued its earnings results on Thursday, February 24th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). During the same period last year, the business earned ($0.46) earnings per share. On average, research analysts predict that Immunic will post -3.28 EPS for the current fiscal year.

Large investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA increased its position in shares of Immunic by 112.9% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 3,553 shares of the company’s stock worth $31,000 after purchasing an additional 1,884 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Immunic during the 1st quarter worth about $34,000. Citigroup Inc. boosted its holdings in Immunic by 93.6% during the 3rd quarter. Citigroup Inc. now owns 3,981 shares of the company’s stock valued at $35,000 after acquiring an additional 1,925 shares during the period. Barclays PLC boosted its holdings in Immunic by 285.7% during the 3rd quarter. Barclays PLC now owns 7,653 shares of the company’s stock valued at $68,000 after acquiring an additional 5,669 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in Immunic by 3,107.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,274 shares of the company’s stock valued at $79,000 after acquiring an additional 8,016 shares during the period. 49.03% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile (Get Rating)

Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.

Read More

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.